Core Viewpoint - The company reported a slight decline in revenue but a significant increase in net profit, driven by improvements in core business efficiency [2][3] Revenue and Profit Performance - In the first half of 2025, the company achieved operating revenue of 855 million yuan, a year-on-year decrease of 4%, while net profit attributable to shareholders reached 147 million yuan, a year-on-year increase of 22% [1][2] - The net profit after deducting non-recurring items was 145 million yuan, reflecting a year-on-year growth of 25.43% [2] Business Segment Analysis - The bioenergy (biodiesel) segment was a key driver of profit growth, generating revenue of 474 million yuan, up 6.38% year-on-year, with a significant reduction in operating costs by 7.22%, leading to a gross margin increase of 9.71 percentage points to 33.77% [2][3] - The traditional biomass waste operation service business also showed steady growth, achieving revenue of 314 million yuan, a year-on-year increase of 12.11% [3] Synthetic Biology Business Development - The synthetic biology manufacturing business made significant progress, with LNT and LNnT products receiving Self-GRAS certification in the U.S., paving the way for market expansion [4] - The company has completed fermentation production of 30 tons of LNnT and is advancing the development of various HMO products [4] Future Earnings Forecast - The company is projected to achieve operating revenues of 2.293 billion, 2.882 billion, and 3.625 billion yuan for 2025-2027, with year-on-year growth rates of 28.03%, 25.68%, and 25.81% respectively [5] - Net profit attributable to shareholders is expected to be 302 million, 405 million, and 519 million yuan for the same period, with growth rates of 40.07%, 34.12%, and 28.19% respectively [5]
朗坤科技(301305)：生物能源盈利能力提升 合成生物业务打开成长新空间